Cargando…

The Effect of Ivermectin on Cases of COVID-19()

Ivermectin is an antiviral agent that has historically had a wide variety of uses. Recently, it has gained popularity in the mainstream media for use in treating and preventing COVID-19 infection, prompting high sales in veterinary grade Ivermectin. Studies are increasingly looking at Ivermectin as...

Descripción completa

Detalles Bibliográficos
Autores principales: Annie, Frank H., Campbell, James, Searls, Lauren, Amos, Jessica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212849/
https://www.ncbi.nlm.nih.gov/pubmed/35729025
http://dx.doi.org/10.1016/j.carrev.2022.06.004
_version_ 1784730700336857088
author Annie, Frank H.
Campbell, James
Searls, Lauren
Amos, Jessica
author_facet Annie, Frank H.
Campbell, James
Searls, Lauren
Amos, Jessica
author_sort Annie, Frank H.
collection PubMed
description Ivermectin is an antiviral agent that has historically had a wide variety of uses. Recently, it has gained popularity in the mainstream media for use in treating and preventing COVID-19 infection, prompting high sales in veterinary grade Ivermectin. Studies are increasingly looking at Ivermectin as a possible agent for prevention and treatment of COVID-19, however further information is needed to assess efficacy and safety. Our project aimed to evaluate mortality differences in patients with COVID-19 infection who were prescribed Ivermectin vs. those not prescribed Ivermectin. Adult patients with active COVID-19 infection who were not prescribed Ivermectin (n = 797,285 Outpatient, n = 481,705 Inpatient, and n = 58,050 Intensive care unit), and those prescribed Ivermectin (n = 804 Outpatient, n = 1774 Inpatient, and n = 107 Intensive care unit) were evaluated. The cohorts were then evaluated for mortality comparing patients prescribed Ivermectin and those not prescribed Ivermectin in the Outpatient (7.7 % vs 2.2 %, P < 0.001), Inpatient not requiring Intensive Care (15.6 % vs 7.2 %, P ≤ 0.001), and Intensive care (20.6 % vs 19.6 %, P = 0.86) treatment settings.
format Online
Article
Text
id pubmed-9212849
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-92128492022-06-22 The Effect of Ivermectin on Cases of COVID-19() Annie, Frank H. Campbell, James Searls, Lauren Amos, Jessica Cardiovasc Revasc Med Research Letters Ivermectin is an antiviral agent that has historically had a wide variety of uses. Recently, it has gained popularity in the mainstream media for use in treating and preventing COVID-19 infection, prompting high sales in veterinary grade Ivermectin. Studies are increasingly looking at Ivermectin as a possible agent for prevention and treatment of COVID-19, however further information is needed to assess efficacy and safety. Our project aimed to evaluate mortality differences in patients with COVID-19 infection who were prescribed Ivermectin vs. those not prescribed Ivermectin. Adult patients with active COVID-19 infection who were not prescribed Ivermectin (n = 797,285 Outpatient, n = 481,705 Inpatient, and n = 58,050 Intensive care unit), and those prescribed Ivermectin (n = 804 Outpatient, n = 1774 Inpatient, and n = 107 Intensive care unit) were evaluated. The cohorts were then evaluated for mortality comparing patients prescribed Ivermectin and those not prescribed Ivermectin in the Outpatient (7.7 % vs 2.2 %, P < 0.001), Inpatient not requiring Intensive Care (15.6 % vs 7.2 %, P ≤ 0.001), and Intensive care (20.6 % vs 19.6 %, P = 0.86) treatment settings. Elsevier Inc. 2022-11 2022-06-17 /pmc/articles/PMC9212849/ /pubmed/35729025 http://dx.doi.org/10.1016/j.carrev.2022.06.004 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Research Letters
Annie, Frank H.
Campbell, James
Searls, Lauren
Amos, Jessica
The Effect of Ivermectin on Cases of COVID-19()
title The Effect of Ivermectin on Cases of COVID-19()
title_full The Effect of Ivermectin on Cases of COVID-19()
title_fullStr The Effect of Ivermectin on Cases of COVID-19()
title_full_unstemmed The Effect of Ivermectin on Cases of COVID-19()
title_short The Effect of Ivermectin on Cases of COVID-19()
title_sort effect of ivermectin on cases of covid-19()
topic Research Letters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212849/
https://www.ncbi.nlm.nih.gov/pubmed/35729025
http://dx.doi.org/10.1016/j.carrev.2022.06.004
work_keys_str_mv AT anniefrankh theeffectofivermectinoncasesofcovid19
AT campbelljames theeffectofivermectinoncasesofcovid19
AT searlslauren theeffectofivermectinoncasesofcovid19
AT amosjessica theeffectofivermectinoncasesofcovid19
AT anniefrankh effectofivermectinoncasesofcovid19
AT campbelljames effectofivermectinoncasesofcovid19
AT searlslauren effectofivermectinoncasesofcovid19
AT amosjessica effectofivermectinoncasesofcovid19